150 related articles for article (PubMed ID: 33434277)
21. Clinical Characteristics of Rheumatoid Arthritis Patients Achieving Functional Remission with Six Months of Biological DMARDs Treatment.
Miwa Y; Takahashi R; Ikari Y; Maeoka A; Nishimi S; Oguro N; Hayashi T; Hatano M; Isojima S; Yanai R; Kasama T; Toyoshima Y; Inagaki K; Sanada K
Intern Med; 2017; 56(8):903-906. PubMed ID: 28420837
[TBL] [Abstract][Full Text] [Related]
22. Biologic treatment for rheumatic disease: real-world big data analysis from the Greek country-wide prescription database.
Sfikakis PP; Bournia VK; Sidiropoulos P; Boumpas DT; Drosos AA; Kitas GD; Konstantonis G; Liossis SN; Manoussakis MN; Sakkas L; Tektonidou M; Tzioufas AG; Vlachoyiannopoulos PG; Kani C; Paterakis P; Litsa P; Vassilopoulos D
Clin Exp Rheumatol; 2017; 35(4):579-585. PubMed ID: 28281458
[TBL] [Abstract][Full Text] [Related]
23. Disease activity measures at baseline predict structural damage progression: data from the randomized, controlled AMPLE and AVERT trials.
Keystone EC; Ahmad HA; Yazici Y; Bergman MJ
Rheumatology (Oxford); 2020 Aug; 59(8):2090-2098. PubMed ID: 31819995
[TBL] [Abstract][Full Text] [Related]
24. Long-term experience with etanercept in the treatment of rheumatoid arthritis in elderly and younger patients: patient-reported outcomes from multiple controlled and open-label extension studies.
Schiff MH; Yu EB; Weinblatt ME; Moreland LW; Genovese MC; White B; Singh A; Chon Y; Woolley JM
Drugs Aging; 2006; 23(2):167-78. PubMed ID: 16536638
[TBL] [Abstract][Full Text] [Related]
25. Higher education is associated with a better rheumatoid arthritis outcome concerning for pain and function but not disease activity: results from the EIRA cohort and Swedish rheumatology register.
Jiang X; Sandberg ME; Saevarsdottir S; Klareskog L; Alfredsson L; Bengtsson C
Arthritis Res Ther; 2015 Nov; 17():317. PubMed ID: 26546562
[TBL] [Abstract][Full Text] [Related]
26. Novel optical spectral transmission (OST)-guided versus conventionally disease activity-guided treatment: study protocol of a randomized clinical trial on guidance of a treat-to-target strategy for early rheumatoid arthritis.
Besselink NJ; Westgeest AAA; Klaasen R; Gamala M; van Woerkom JM; Tekstra J; Verhoeven MMA; Van Spil WE; Lafeber FPJG; Marijnissen ACA; Van Laar JM; Jacobs JWG
Trials; 2019 Apr; 20(1):226. PubMed ID: 30999969
[TBL] [Abstract][Full Text] [Related]
27. Are there differences between young- and older-onset early inflammatory arthritis and do these impact outcomes? An analysis from the CATCH cohort.
Arnold MB; Bykerk VP; Boire G; Haraoui BP; Hitchon C; Thorne C; Keystone EC; Pope JE;
Rheumatology (Oxford); 2014 Jun; 53(6):1075-86. PubMed ID: 24501240
[TBL] [Abstract][Full Text] [Related]
28. What is the outcome of RA in 2011 and can we predict it?
Verstappen SM; Symmons DP
Best Pract Res Clin Rheumatol; 2011 Aug; 25(4):485-96. PubMed ID: 22137919
[TBL] [Abstract][Full Text] [Related]
29. Effectiveness of maintenance therapy with methotrexate compared with leflunomide for patients with RA having achieved disease control with both these drugs: results of a predefined sub-analysis of CareRA, a pragmatic RCT.
Stouten V; Michiels S; Westhovens R; De Cock D; Belba A; Pazmino S; Van der Elst K; Joly J; Verschueren P
Clin Rheumatol; 2020 Sep; 39(9):2593-2601. PubMed ID: 32166429
[TBL] [Abstract][Full Text] [Related]
30. The Use of Rheumatic Disease Comorbidity Index for Predicting Clinical Response and Retention Rate in a Cohort of Rheumatoid Arthritis Patients Receiving Tumor Necrosis Factor Alpha Inhibitors.
Biggioggero M; Mesina F; Favalli EG
Biomed Res Int; 2019; 2019():6107217. PubMed ID: 30733963
[TBL] [Abstract][Full Text] [Related]
31. Predictors of remission with etanercept-methotrexate induction therapy and loss of remission with etanercept maintenance, reduction, or withdrawal in moderately active rheumatoid arthritis: results of the PRESERVE trial.
Smolen JS; Szumski A; Koenig AS; Jones TV; Marshall L
Arthritis Res Ther; 2018 Jan; 20(1):8. PubMed ID: 29338762
[TBL] [Abstract][Full Text] [Related]
32. Three out of four disease-modifying anti-rheumatic drug-naïve rheumatoid arthritis patients meet 28-joint Disease Activity Score remission at 12 months: results from the FIN-ERA cohort.
Rannio T; Asikainen J; Hannonen P; Yli-Kerttula T; Ekman P; Pirilä L; Kuusalo L; Mali M; Puurtinen-Vilkki M; Kortelainen S; Paltta J; Taimen K; Kauppi M; Laiho K; Nyrhinen S; Mäkinen H; Isomäki P; Uotila T; Aaltonen K; Kautiainen H; Sokka T
Scand J Rheumatol; 2017 Nov; 46(6):425-431. PubMed ID: 28367663
[TBL] [Abstract][Full Text] [Related]
33. Self-reported comorbidity is common in early inflammatory arthritis and associated with poorer function and worse arthritis disease outcomes: results from the Canadian Early Arthritis Cohort.
Hitchon CA; Boire G; Haraoui B; Keystone E; Pope J; Jamal S; Tin D; Thorne C; Bykerk VP;
Rheumatology (Oxford); 2016 Oct; 55(10):1751-62. PubMed ID: 27330161
[TBL] [Abstract][Full Text] [Related]
34. Flares in Rheumatoid Arthritis Patients with Low Disease Activity: Predictability and Association with Worse Clinical Outcomes.
Bechman K; Tweehuysen L; Garrood T; Scott DL; Cope AP; Galloway JB; Ma MHY
J Rheumatol; 2018 Nov; 45(11):1515-1521. PubMed ID: 30173149
[TBL] [Abstract][Full Text] [Related]
35. M-ficolin levels reflect disease activity and predict remission in early rheumatoid arthritis.
Ammitzbøll CG; Thiel S; Jensenius JC; Ellingsen T; Hørslev-Petersen K; Hetland ML; Junker P; Krogh NS; Østergaard M; Stengaard-Pedersen K
Arthritis Rheum; 2013 Dec; 65(12):3045-50. PubMed ID: 24022747
[TBL] [Abstract][Full Text] [Related]
36. Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy: The FINCH 2 Randomized Clinical Trial.
Genovese MC; Kalunian K; Gottenberg JE; Mozaffarian N; Bartok B; Matzkies F; Gao J; Guo Y; Tasset C; Sundy JS; de Vlam K; Walker D; Takeuchi T
JAMA; 2019 Jul; 322(4):315-325. PubMed ID: 31334793
[TBL] [Abstract][Full Text] [Related]
37. Patients with rheumatoid arthritis have better functional and working ability but poorer general health and higher comorbidity rates today than in the late 1990s.
Uutela T; Kautiainen H; Järvenpää S; Salomaa S; Hakala M; Häkkinen A
Scand J Rheumatol; 2015 May; 44(3):173-81. PubMed ID: 25438985
[TBL] [Abstract][Full Text] [Related]
38. Joint damage progression in patients with rheumatoid arthritis in clinical remission: do biologics perform better than synthetic antirheumatic drugs?
Ciubotariu E; Gabay C; Finckh A;
J Rheumatol; 2014 Aug; 41(8):1576-82. PubMed ID: 25028383
[TBL] [Abstract][Full Text] [Related]
39. Harm, benefit and costs associated with low-dose glucocorticoids added to the treatment strategies for rheumatoid arthritis in elderly patients (GLORIA trial): study protocol for a randomised controlled trial.
Hartman L; Rasch LA; Klausch T; Bijlsma HWJ; Christensen R; Smulders YM; Ralston SH; Buttgereit F; Cutolo M; Da Silva JAP; Opris D; Rovenský J; Szamosi S; Middelink LM; Lems WF; Boers M
Trials; 2018 Jan; 19(1):67. PubMed ID: 29370811
[TBL] [Abstract][Full Text] [Related]
40. Tofacitinib with conventional synthetic disease-modifying antirheumatic drugs in Chinese patients with rheumatoid arthritis: Patient-reported outcomes from a Phase 3 randomized controlled trial.
Li Z; An Y; Su H; Li X; Xu J; Zheng Y; Li G; Kwok K; Wang L; Wu Q
Int J Rheum Dis; 2018 Feb; 21(2):402-414. PubMed ID: 29314645
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
